Update shared on 28 Nov 2025
Analysts have raised their price target for CorMedix to $14 from the previous level, citing stronger than expected Q3 sales and improved visibility into operational performance as key drivers of the updated outlook.
Analyst Commentary
Following the recent preliminary Q3 results, analysts have provided updated insights into CorMedix’s outlook, highlighting both encouraging signs and ongoing areas of caution for the company’s future performance.
Bullish Takeaways
- Bullish analysts point to stronger than anticipated Q3 sales as a significant indicator of effective execution and growing market demand.
- Improved visibility into operational synergies is seen as a driver for achieving greater efficiencies in the near term. This may potentially support margin expansion.
- Recent stock pullback is viewed as creating a more attractive entry point. The updated price target reflects confidence in a rebound.
- Raised outlook underscores confidence in both the company’s valuation and its ability to sustain sales growth in subsequent quarters.
Bearish Takeaways
- Bearish analysts remain cautious about long-term execution risks as the company integrates and scales its operations.
- Visibility into operating synergies is still developing. Realizing projected cost savings will be essential to maintain momentum.
- There is some concern regarding the sustainability of sales momentum beyond the initial strong quarter, particularly if competitive pressures increase.
What's in the News
- CorMedix Inc. provided earnings guidance for Q4 2025, with projected net revenue in the range of $115 to $135 million. (Key Developments)
- The company announced revised full-year 2025 revenue guidance, now estimated at $325 to $350 million. (Key Developments)
- Susan Blum has been appointed as Chief Financial Officer, effective August 29, 2025. (Key Developments)
- CorMedix completed enrollment for its ongoing global Phase III ReSPECT trial studying REZZAYO® for antifungal prophylaxis in allogeneic BMT patients. (Key Developments)
- The company proposed amendments to its Certificate of Incorporation, impacting voting rights for holders of preferred and common stock. (Key Developments)
Valuation Changes
- Fair Value Estimate remains steady at $19.00, showing no change from the previous update.
- Discount Rate has remained the same at 6.96%.
- Revenue Growth has increased modestly, rising from 28.35% to 28.79%.
- Net Profit Margin has improved, moving from 45.65% to 47.86%.
- Future P/E has fallen moderately, shifting from 10.79x to 10.19x.
Have other thoughts on CorMedix?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.